Sangamo Therapeutics Inc [NASDAQ: SGMO] price plunged by -7.45 percent to reach at -$0.14.
The one-year SGMO stock forecast points to a potential upside of 54.21. The average equity rating for SGMO stock is currently 2.12, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Sangamo Therapeutics Inc [SGMO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SGMO shares is $3.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SGMO stock is a recommendation set at 2.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Sangamo Therapeutics Inc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on November 03, 2023. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $5 to $1.50. The new note on the price target was released on April 28, 2023, representing the official price target for Sangamo Therapeutics Inc stock. Previously, the target price had yet another raise to $16, while Wedbush analysts kept a Outperform rating on SGMO stock. On January 06, 2023, analysts decreased their price target for SGMO shares from 8 to 5.
The Average True Range (ATR) for Sangamo Therapeutics Inc is set at 0.23, with the Price to Sales ratio for SGMO stock in the period of the last 12 months amounting to 32.63. The Price to Book ratio for the last quarter was 15.29, with the Price to Cash per share for the same quarter was set at 0.12.
SGMO Stock Performance Analysis:
Sangamo Therapeutics Inc [SGMO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.71. With this latest performance, SGMO shares gained by 122.79% in over the last four-week period, additionally plugging by 230.48% over the last 6 months – not to mention a rise of 278.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SGMO stock in for the last two-week period is set at 64.44, with the RSI for the last a single of trading hit 61.78, and the three-weeks RSI is set at 64.99 for Sangamo Therapeutics Inc [SGMO]. The present Moving Average for the last 50 days of trading for this stock 1.0218, while it was recorded at 1.8620 for the last single week of trading, and 0.7437 for the last 200 days.
Insight into Sangamo Therapeutics Inc Fundamentals:
Sangamo Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.03 and a Current Ratio set at 1.03.
Sangamo Therapeutics Inc [SGMO] Institutonal Ownership Details
There are presently around $42.20%, or 43.23%% of SGMO stock, in the hands of institutional investors. The top three institutional holders of SGMO stocks are: WASATCH ADVISORS LP with ownership of 20.09 million shares, which is approximately 11.1403%. ARMISTICE CAPITAL, LLC, holding 14.06 million shares of the stock with an approximate value of $$5.04 million in SGMO stocks shares; and ARMISTICE CAPITAL, LLC, currently with $$4.26 million in SGMO stock with ownership which is approximately 6.5977%.
